File Download
  Patent History
  • Application
    US 12/469319 2009-05-20
  • Publication
    US 2009298797 2009-12-03
Supplementary

published patent: COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA

TitleCOMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA
Priority Date2009-05-20 US 12/469319
2008-05-23 US 12/055573P
Inventors
Issue Date2009
Citation
US Published patent application US 2009298797. Washington, DC: US Patent and Trademark Office (USPTO), 2009 How to Cite?
AbstractCompositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject.
Persistent Identifierhttp://hdl.handle.net/10722/176984

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:53Z-
dc.date.available2012-11-30T08:38:53Z-
dc.date.issued2009-
dc.identifier.citationUS Published patent application US 2009298797. Washington, DC: US Patent and Trademark Office (USPTO), 2009en_HK
dc.identifier.urihttp://hdl.handle.net/10722/176984-
dc.description.abstractCompositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleCOMBINATION THERAPY FOR THE TREATMENT OF INFLUENZAen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorZheng, Ben_HK
dc.contributor.inventorYuen, KYen_HK
patents.identifier.applicationUS 12/469319en_HK
patents.description.assigneeUNIV HONG KONGen_HK
patents.description.countryUnited States of Americaen_HK
patents.date.publication2009-12-03en_HK
patents.identifier.hkutechidMicro-2008-00283-
patents.date.application2009-05-20en_HK
patents.date.priority2009-05-20 US 12/469319en_HK
patents.date.priority2008-05-23 US 12/055573Pen_HK
patents.description.ccUSen_HK
patents.identifier.publicationUS 2009298797en_HK
patents.relation.familyCN 102036658 (A) 2011-04-27en_HK
patents.relation.familyUS 2009298797 (A1) 2009-12-03en_HK
patents.relation.familyWO 2009140853 (A1) 2009-11-26en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats